IP Library Granted Patent US 10,064,943
Granted Patent B2
US 10,064,943 · App. 14/728,247 · Granted Sep 4, 2018

Therapeutic and diagnostic probes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,943
App. No.
14/728,247
Granted
Sep 4, 2018
Kind
B2
Abstract

The present invention provides compositions and methods of use of nanoparticle-based probes for in vivo imaging and therapy. The probes can be used to track diseased target cells by non-invasive imaging in the near-infrared range. Additionally, the probes can induce cell death of the target cells via photodynamic treatment.

Claims (13)

1. A probe comprising a nanocarrier attached to both (1) an imaging agent, wherein the imaging agent is a cyanine dye; and (2) a therapeutic agent, which is IRDYE700DX, wherein said nanocarrier is an antibody or a fragment thereof.

2. The probe of claim 1 , wherein said therapeutic agent is attached to said nanocarrier via a first linker.

3. The probe of claim 2 , wherein said imaging agent is attached to said nanocarrier via a second linker.

4. A method for detecting a target cell in an individual, said method comprising:

(a) contacting said target cell with a probe comprising a nanocarrier attached to both (1) an imaging agent, which imaging agent is a cyanine dye; and (2) a therapeutic agent, wherein the therapeutic agent is IRDYE700DX, wherein the probe selectively associates with the said target cell, wherein said nanocarrier is an antibody or fragment thereof; and

(b) detecting said imaging agent thereby providing an indication of the presence and/or location of said target cell in the individual.

5. The method of claim 4 , wherein said contacting comprises systemic administration to the individual, local administration to a tumor, or administration to a surgical site.

6. The method of claim 4 , wherein said target cell is a cell of a solid tumor.

7. The method claim 4 , further comprising exposing said therapeutic agent to a photoactivating light, thereby inducing apoptosis and/or necrosis of said target cell in the individual.

8. A method for inducing cell death in a target cell in an individual, said method comprising:

(a) contacting said target cell with a probe comprising a nanocarrier attached to both (1) an imaging agent, which imaging agent is a cyanine dye; and (2) a therapeutic agent, wherein the therapeutic agent is IRDYE700DX, wherein the probe selectively associates with said target cell, wherein said nanocarrier is an antibody or fragment thereof; and

(b) exposing said therapeutic agent to a photoactivating light, thereby inducing apoptosis and/or necrosis of said target cell in the individual.

9. The method of claim 8 , wherein said contacting comprises systemic administration to the individual, local administration to a tumor, or administration to a surgical site.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: LI-COR, INC.
To: RAKUTEN MEDICAL, INC.
Reel/Frame 055238/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2017
From: KOVAR, JOY
To: LI-COR, INC.
Reel/Frame 041216/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2015
From: DILLEY, DAVID L.
To: LI-COR, INC.
Reel/Frame 035899/0274 →
Cited By (3)
US 12,383,620 US 12,491,249 US 12,704,501